Q3 CY2026 Quarterly Activities Report & Form 10-Q Submission

• U.S. commercial launch commenced with Rady Children's Hospital-San Diego as first customer
• FDA cleared pediatric label expansions for NorthStar and Vision-MR Diagnostic Catheter
• Philips compatibility declaration and joint iMR lab solution launched
• Imricor Finance introduced to ease hospital purchasing decisions
• Revenue of US$188k, up 437% from the prior corresponding period

Imricor Medical Systems, Inc. (ASX: IMR) has successfully launched its U.S. commercial operations, marking a significant milestone in its growth strategy. The company's first commercial U.S. customer, Rady Children's Hospital-San Diego, has established the country's first commercial interventional MR cardiac catheterization program. Additionally, Children's Medical Center Dallas became Imricor's second U.S. customer. Regulatory progress includes FDA clearances for pediatric label expansions and the acceptance of the manufacturing module for the Vision-MR Ablation Catheter PMA application. Strategic partnerships with Philips have opened the Philips installed base to Imricor's iMR equipment. Financially, the company reported revenue of US$188k for the quarter, up 437% from the prior corresponding period.

The remainder of CY2026 will focus on executing the U.S. commercial launch, converting the hospital pipeline into NorthStar sales, and scaling the U.S. commercial organization.